ATC Group: A07EC03 Olsalazine

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of A07EC03 in the ATC hierarchy

Level Code Title
1 A Alimentary tract and metabolism
2 A07 Antidiarrheals, intestinal antiinflammatory/antiinfective agents
3 A07E Intestinal antiinflammatory agents
4 A07EC Aminosalicylic acid and similar agents
5 A07EC03 Olsalazine

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
ORAL - Oral 1 g

Active ingredients in A07EC03

Active Ingredient Description
Olsalazine

Olsalazine is bioconverted to 5-aminosalicylic acid (5-ASA), which has anti-inflammatory activity in ulcerative colitis. The conversion of olsalazine to mesalamine (5-ASA) in the colon is similar to that of sulfasalazine, which is converted into sulfapyridine and mesalamine. The mechanism of action of mesalamine (and sulfasalazine) is unknown, but appears to be topical rather than systemic.

Related product monographs

Title Information Source Document Type  
DIPENTUM Capsule FDA, National Drug Code (US) MPI, US: SPL/Old

Medicines in this ATC group

United States (US)

Australia (AU)

Canada (CA)

Finland (FI)

France (FR)

Ireland (IE)

Netherlands (NL)

New Zealand (NZ)

South Africa (ZA)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.